Ascletis Pharma (HKG:1672) said it has been included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective Sept. 7.
The inclusion allows mainland Chinese investors to trade the biotech company's Hong Kong-listed shares through the Stock Connect platform, according to a Monday Hong Kong bourse filing.
Shares of the drugmaker rose over 2% in recent trade.